StockDuty ← Dashboard Nov 06, 2026 03:02 AM ET
SignalCorporate

Castle Biosciences signals $385M-$395M 2026 revenue outlook as TissueCypher targets 50%-52% volume growth

Castle Biosciences signals $385M-$395M 2026 revenue outlook with TissueCypher targeting 50%-52% volume growth.

Castle Biosciences signals $385M-$395M 2026 revenue outlook with TissueCypher targeting 50%-52% volume growth.
Castle Biosciences signals $385M-$395M 2026 revenue outlook with TissueCypher targeting 50%-52% volume growth. — impact context not separately stored; see What changed.
Sources